195 related articles for article (PubMed ID: 10227113)
1. Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro.
Bymaster FP; Nelson DL; DeLapp NW; Falcone JF; Eckols K; Truex LL; Foreman MM; Lucaites VL; Calligaro DO
Schizophr Res; 1999 May; 37(1):107-22. PubMed ID: 10227113
[TBL] [Abstract][Full Text] [Related]
2. The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors.
Zhang W; Bymaster FP
Psychopharmacology (Berl); 1999 Jan; 141(3):267-78. PubMed ID: 10027508
[TBL] [Abstract][Full Text] [Related]
3. Radioreceptor binding profile of the atypical antipsychotic olanzapine.
Bymaster FP; Calligaro DO; Falcone JF; Marsh RD; Moore NA; Tye NC; Seeman P; Wong DT
Neuropsychopharmacology; 1996 Feb; 14(2):87-96. PubMed ID: 8822531
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo biochemistry of olanzapine: a novel, atypical antipsychotic drug.
Bymaster FP; Rasmussen K; Calligaro DO; Nelson DL; DeLapp NW; Wong DT; Moore NA
J Clin Psychiatry; 1997; 58 Suppl 10():28-36. PubMed ID: 9265914
[TBL] [Abstract][Full Text] [Related]
5. Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, alpha 1-adrenergic and muscarinic receptors in vivo in rats.
Bymaster FP; Hemrick-Luecke SK; Perry KW; Fuller RW
Psychopharmacology (Berl); 1996 Mar; 124(1-2):87-94. PubMed ID: 8935803
[TBL] [Abstract][Full Text] [Related]
6. Effects of clozapine on rat striatal muscarinic receptors coupled to inhibition of adenylyl cyclase activity and on the human cloned m4 receptor.
Olianas MC; Maullu C; Onali P
Br J Pharmacol; 1997 Oct; 122(3):401-8. PubMed ID: 9351494
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of olanzapine at dopamine D1 and D2 receptors in dopamine depleted animals.
Ninan I; Kulkarni SK
Psychopharmacology (Berl); 1999 Feb; 142(2):175-81. PubMed ID: 10102770
[TBL] [Abstract][Full Text] [Related]
8. Olanzapine: a basic science update.
Bymaster F; Perry KW; Nelson DL; Wong DT; Rasmussen K; Moore NA; Calligaro DO
Br J Psychiatry Suppl; 1999; (37):36-40. PubMed ID: 10211140
[TBL] [Abstract][Full Text] [Related]
9. Rat striatal muscarinic receptors coupled to the inhibition of adenylyl cyclase activity: potent block by the selective m4 ligand muscarinic toxin 3 (MT3).
Olianas MC; Adem A; Karlsson E; Onali P
Br J Pharmacol; 1996 May; 118(2):283-8. PubMed ID: 8735628
[TBL] [Abstract][Full Text] [Related]
10. Functional effects of the muscarinic receptor agonist, xanomeline, at 5-HT1 and 5-HT2 receptors.
Watson J; Brough S; Coldwell MC; Gager T; Ho M; Hunter AJ; Jerman J; Middlemiss DN; Riley GJ; Brown AM
Br J Pharmacol; 1998 Dec; 125(7):1413-20. PubMed ID: 9884068
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the new atypical antipsychotics olanzapine and ICI 204,636 with clozapine on behavioural responses to the selective "D1-like" dopamine receptor agonist A 68930 and selective "D2-like" agonist RU 24213.
Deveney AM; Waddington JL
Psychopharmacology (Berl); 1996 Mar; 124(1-2):40-9. PubMed ID: 8935799
[TBL] [Abstract][Full Text] [Related]
12. Preclinical pharmacology of FMPD [6-fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H-3-thia-4,9-diaza-benzo[f]azulene]: a potential novel antipsychotic with lower histamine H1 receptor affinity than olanzapine.
Rasmussen K; Benvenga MJ; Bymaster FP; Calligaro DO; Cohen IR; Falcone JF; Hemrick-Luecke SK; Martin FM; Moore NA; Nisenbaum LK; Schaus JM; Sundquist SJ; Tupper DE; Wiernicki TR; Nelson DL
J Pharmacol Exp Ther; 2005 Dec; 315(3):1265-77. PubMed ID: 16141369
[TBL] [Abstract][Full Text] [Related]
13. Potent antagonism of 5-HT(3) and 5-HT(6) receptors by olanzapine.
Bymaster FP; Falcone JF; Bauzon D; Kennedy JS; Schenck K; DeLapp NW; Cohen ML
Eur J Pharmacol; 2001 Nov; 430(2-3):341-9. PubMed ID: 11711053
[TBL] [Abstract][Full Text] [Related]
14. Benzo- and thienobenzo- diazepines: multi-target drugs for CNS disorders.
Mendonça Júnior FJ; Scotti L; Ishiki H; Botelho SP; Da Silva MS; Scotti MT
Mini Rev Med Chem; 2015; 15(8):630-47. PubMed ID: 25694077
[TBL] [Abstract][Full Text] [Related]
15. Extended radioligand binding profile of iloperidone: a broad spectrum dopamine/serotonin/norepinephrine receptor antagonist for the management of psychotic disorders.
Kalkman HO; Subramanian N; Hoyer D
Neuropsychopharmacology; 2001 Dec; 25(6):904-14. PubMed ID: 11750183
[TBL] [Abstract][Full Text] [Related]
16. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature.
Shahid M; Walker GB; Zorn SH; Wong EH
J Psychopharmacol; 2009 Jan; 23(1):65-73. PubMed ID: 18308814
[TBL] [Abstract][Full Text] [Related]
17. 5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex.
Rollema H; Lu Y; Schmidt AW; Sprouse JS; Zorn SH
Biol Psychiatry; 2000 Aug; 48(3):229-37. PubMed ID: 10924666
[TBL] [Abstract][Full Text] [Related]
18. [35S]Guanosine-5'-O-(3-thio)triphosphate binding as a measure of efficacy at human recombinant dopamine D4.4 receptors: actions of antiparkinsonian and antipsychotic agents.
Newman-Tancredi A; Audinot V; Chaput C; Verrièle L; Millan MJ
J Pharmacol Exp Ther; 1997 Jul; 282(1):181-91. PubMed ID: 9223553
[TBL] [Abstract][Full Text] [Related]
19. Neuropharmacology of zotepine, an antimanic drug: a potent blocker of D2 and 5-HT2 receptors of human brain.
Kanba S; Yagi G; Oguchi E; Nakaki T; Kato R; Richelson E
Jpn J Psychiatry Neurol; 1991 Mar; 45(1):133-4. PubMed ID: 1684393
[No Abstract] [Full Text] [Related]
20. PD 102807, a novel muscarinic M4 receptor antagonist, discriminates between striatal and cortical muscarinic receptors coupled to cyclic AMP.
Olianas MC; Onali P
Life Sci; 1999; 65(21):2233-40. PubMed ID: 10576595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
